Entry Point Capital, LLC Adma Biologics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 6,433 shares of ADMA stock, worth $109,103. This represents 0.11% of its overall portfolio holdings.
Number of Shares
6,433
Previous 4,740
35.72%
Holding current value
$109,103
Previous $31.3 Million
129.9%
% of portfolio
0.11%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding ADMA
# of Institutions
278Shares Held
177MCall Options Held
535KPut Options Held
21.2K-
Black Rock Inc. New York, NY18.6MShares$316 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$246 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA13.2MShares$223 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.93MShares$151 Million0.03% of portfolio
-
State Street Corp Boston, MA8.06MShares$137 Million0.0% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.33B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...